SIENA, Italy /PRNewswire/ --
Philogen S.p.A. (a privately-owned company) today announced that they have entered into a collaboration and license agreement with Celgene, to discover and develop a new class of immunomodulatory therapeutics.
"We are extremely pleased to establish a new collaboration with Celgene, a leader in the discovery and development and commercialization of innovative therapies for patients with high unmet medical needs," commented Dr. Duccio Neri, Philogen's CEO.
No financial details of the agreement were released.
